Literature DB >> 1314700

Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma.

M W Höhne1, M E Halatsch, G F Kahl, R J Weinel.   

Abstract

The development of colon carcinomas is associated with allelic deletions on chromosomes 5q, 17p, and 18q. The DCC gene located on chromosome 18q21.3 codes for a potential tumor suppressor gene related to cellular adhesion receptors. We investigated the expression of this gene in several pancreatic carcinoma cell lines and in patients with ductal adenocarcinomas of the pancreas. In 8 of 11 cell lines and in 4 of 8 primary tumors a complete extinction of DCC gene expression was observed, whereas the c-Ki-ras gene was mutated at codon 12 in 7 of 8 tumors. A highly reduced or absent expression of DCC was found in all low or undifferentiated pancreatic tumor cell lines, whereas in the more differentiated ones DCC expression was conserved. These data suggest that loss of DCC gene expression is an important factor in the development or progress of pancreatic adenocarcinoma and may be linked to the differentiated phenotype of the pancreatic tumor cell.

Entities:  

Mesh:

Year:  1992        PMID: 1314700

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  K-ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers.

Authors:  K Sugio; K Molberg; J Albores-Saavedra; A K Virmani; Y Kishimoto; A F Gazdar
Journal:  Int J Pancreatol       Date:  1997-06

Review 2.  K-ras mutation and pancreatic adenocarcinoma.

Authors:  C Caldas; S E Kern
Journal:  Int J Pancreatol       Date:  1995-08

Review 3.  The use of molecular technology in the differentiation of pancreatic cancer and chronic pancreatitis.

Authors:  S R Bramhall
Journal:  Int J Pancreatol       Date:  1998-04

4.  Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.

Authors:  X Qian; V L Rothman; R F Nicosia; G P Tuszynski
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

5.  Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells.

Authors:  Elisabetta Ceni; Tommaso Mello; Mirko Tarocchi; David-W Crabb; Anna Caldini; Pietro Invernizzi; Calogero Surrenti; Stefano Milani; Andrea Galli
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

6.  Loss of heterozygosity and loss of expression of the DCC gene in gastric cancer.

Authors:  D C Fang; J R Jass; D X Wang
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

7.  Decreased expression of the DCC gene in human breast carcinoma.

Authors:  K Wakita; N Kohno; Y Sakoda; Y Ishikawa; M Sakaue
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

8.  Decreased expression of DCC mRNA in gastric and colorectal cancer.

Authors:  M Kataoka; T Okabayashi; K Orita
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

Review 9.  Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors.

Authors:  H Friess; P Berberat; M Schilling; J Kunz; M Korc; M W Büchler
Journal:  J Mol Med (Berl)       Date:  1996-01       Impact factor: 4.599

10.  Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.

Authors:  A Galli; E Ceni; D W Crabb; T Mello; R Salzano; C Grappone; S Milani; E Surrenti; C Surrenti; A Casini
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.